Finance
Drug discovery company announces 2003 net loss of $3,925,000
Published in Hepatitis Weekly, January 12th, 2004
The company reported a net loss attributable to common stockholders of $3,925,000, or $.29 per share.
For the previous fiscal year ended September 30, 2002, the company had a net loss attributable to common stockholders of $12,189,000, or $.94 per share. For the quarter ended September 30, 2003, Incara had a net loss attributable to common stockholders of $1,315,000 or $.10 per share. For the quarter ended September 30, 2002, Incara had a net loss attributable to common stockholders of $2,740,000, or $.20 per share. Financial results for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-01-12)
More Articles from Hepatitis Weekly
- Hepatitis C Therapy
Consolidation therapy improves sustained response in HCV genotype 1b patients - Cirrhosis
TIPS improves cardiac function in hypovolemic patients - Collaborations
Nonexclusive HCV license granted to Boehringer Ingelheim - Finance
Gene identification company reports 73.7% gross profit margin - Gastroenterology
TNF-alpha may play an early role in the malignant transformation of liver cells - HIV/AIDS Coinfection
Hepatitis B treatment for HIV patients reviewed - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
